Diabetic Nephropathy News | Diabetes & Renal Research Studies

Diabetic Nephropathy


Invokana sNDA Seeking Treatment of Chronic Kidney Disease in T2D Patients

Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
Next post in Diabetic Nephropathy